The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2026.
All research outputs
#8,564,353
of 32,921,030 outputs
Outputs from The Lancet Respiratory Medicine
#1,979
of 3,290 outputs
Outputs of similar age
#77,986
of 325,365 outputs
Outputs of similar age from The Lancet Respiratory Medicine
#38
of 53 outputs
Altmetric has tracked 32,921,030 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 3,290 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 74.0. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,365 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
